A detailed history of Versant Capital Management, Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 161 shares of VRTX stock, worth $72,509. This represents 0.02% of its overall portfolio holdings.

Number of Shares
161
Previous 132 21.97%
Holding current value
$72,509
Previous $61,000 21.31%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$460.0 - $505.78 $13,340 - $14,667
29 Added 21.97%
161 $74,000
Q2 2024

Jul 05, 2024

BUY
$392.81 - $485.53 $38,495 - $47,581
98 Added 288.24%
132 $61,000
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $3,144 - $3,519
10 Added 41.67%
34 $11,000
Q4 2021

Jan 06, 2022

SELL
$177.01 - $223.45 $1,239 - $1,564
-7 Reduced 22.58%
24 $5,000
Q3 2021

Oct 29, 2021

SELL
$181.39 - $202.99 $9,250 - $10,352
-51 Reduced 62.2%
31 $6,000
Q2 2021

Jul 22, 2021

BUY
$187.49 - $221.1 $2,437 - $2,874
13 Added 18.84%
82 $17,000
Q1 2021

Apr 27, 2021

BUY
$207.02 - $241.31 $8,901 - $10,376
43 Added 165.38%
69 $15,000
Q1 2020

Apr 17, 2020

BUY
$199.77 - $247.81 $599 - $743
3 Added 13.04%
26 $6,000
Q3 2019

Oct 18, 2019

SELL
$166.23 - $187.09 $1,994 - $2,245
-12 Reduced 34.29%
23 $3,000
Q2 2019

Jul 16, 2019

SELL
$164.61 - $190.37 $4,279 - $4,949
-26 Reduced 42.62%
35 $6,000
Q1 2019

Apr 23, 2019

BUY
$163.73 - $194.7 $8,186 - $9,735
50 Added 454.55%
61 $11,000
Q1 2019

Apr 23, 2019

SELL
$163.73 - $194.7 $8,186 - $9,735
-50 Reduced 81.97%
11 $11,000
Q4 2016

Apr 23, 2018

SELL
N/A
-52 Reduced 46.02%
61 $4,000
Q3 2016

Apr 23, 2018

BUY
N/A
15 Added 15.31%
113 $9,000
Q4 2015

Apr 23, 2018

BUY
N/A
98
98 $12,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.